| Cardiac evaluation of mitoxantrone. | |
| | |
MedLine Citation:
|
PMID: 6850653 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Mitoxantrone is a synthetic anthraquinone that was developed through the doxorubicin analog program in hopes of retaining anticancer activity with less cardiotoxicity. This study evaluated 18 patients receiving mitoxantrone with serial noninvasive tests of left ventricular function and with endomyocardial biopsy. The echocardiograms and systolic time intervals demonstrated a trend to deterioration that did not achieve statistical significance. However, the nuclear angiographic ejection fraction significantly decreased from 61% +/- 6% (means +/- SD) at baseline to 58% +/- 5% (P less than 0.05) after 48 mg/m2 of mitoxantrone. The endomyocardial biopsies revealed tubular swelling, degeneration of mitochondria, minimal chromatin clumping, and myofibrillar lysis. This study has revealed mild but definite impairment of cardiac function and mild changes of myocardial morphology during mitoxantrone therapy. Although mitoxantrone is an effective chemotherapeutic agent, a direct comparison of mitoxantrone with doxorubicin is necessary to compare relative therapeutic to cardiotoxic ratios. |
| | |
Authors:
|
D V Unverferth; B J Unverferth; S P Balcerzak; T A Bashore; J A Neidhart |
Related Documents
:
|
2918433 - Eosinophil activation in acute and chronic chagasic myocardial lesions and deposition o... 20035743 - Left ventricular enlargement in coxsackievirus-b3 induced chronic myocarditis--ongoing ... 16720423 - Percutaneous closure of a residual ventricular septal defect in a challenging patient. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Cancer treatment reports Volume: 67 ISSN: 0361-5960 ISO Abbreviation: Cancer Treat Rep Publication Date: 1983 Apr |
Date Detail:
|
Created Date: 1983-07-08 Completed Date: 1983-07-08 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7607107 Medline TA: Cancer Treat Rep Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 343-50 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Anthraquinones / adverse effects* Antineoplastic Agents / adverse effects* Biopsy Female Heart Failure / chemically induced*, pathology Heart Function Tests Humans Male Middle Aged Mitoxantrone Myocardium / pathology, ultrastructure Neoplasms / drug therapy* Stroke Volume |
| Grant Support | |
ID/Acronym/Agency:
|
CA-05147/CA/NCI NIH HHS; CA-16058/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anthraquinones; 0/Antineoplastic Agents; 65271-80-9/Mitoxantrone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hypermetabolism of phenytoin as a cause of treatment failure.
Next Document: High-dose cytarabine in acute leukemia: toxicity and pharmacokinetics.